Actively Recruiting
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
Led by ScreenCell · Updated on 2026-04-24
93
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
Sponsors
S
ScreenCell
Lead Sponsor
A
AXELYS SANTE
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the use of liquid biopsy with ScreenCell technology to detect and measure circulating tumor cells (CTCs) in women during breast cancer follow-up. The study focuses on how the number of CTCs changes over time and aims to provide information on the stage and molecular characteristics of breast cancer during patient monitoring. The study involves three groups: women with no cancer history confirmed by a recent negative mammogram, women with metastatic breast cancer or relapse confirmed by a positive PET scan, and women with invasive but non-metastatic breast cancer. The ScreenCell device is used on blood samples taken from participants to detect CTCs. The study is non-randomized and does not involve any masking or blinding. Participants will be followed for 9 months from enrollment to track changes in CTC levels and their molecular characteristics. Assessments include blood sample collection for CTC detection, with monitoring throughout treatment or follow-up. The primary outcome is the evolution of CTC kinetics during treatment, while secondary outcomes analyze molecular features of detected CTCs.
CONDITIONS
Brief Title
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 years or older
- Participants with metastatic breast cancer or metastatic relapse with change of therapy at inclusion
- Participants with non-metastatic invasive breast cancer who have not received any treatment at inclusion
- Healthy female volunteers with no cancer history and a normal mammogram within two years before inclusion
You will not qualify if you...
- Male
- Age under 18 years
- Refusal to participate or withdrawal of consent
- Pregnant and/or breastfeeding women
- Discovery of a cancer other than breast cancer during follow-up
- Healthy volunteers with history of cancer
- Healthy volunteers with positive circulating tumor cell detection during screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 9 months
Participants provide blood samples during their breast cancer follow-up to evaluate circulating tumor cells using the ScreenCell device.
Multiple visits for blood sample collection during follow-up
Trial Site Locations
Total: 1 location
1
CMC Ambroise Paré Hartmann
Neuilly-sur-Seine, France, 92200
Actively Recruiting
Research Team
J
Jessica GROULT, Ph.D
S
Sina NASERIAN, Ph.D
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here